This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Actavis PLC (ACT): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Actavis ( ACT) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.1%. By the end of trading, Actavis rose $6.52 (3.3%) to $204.33 on average volume. Throughout the day, 3,800,359 shares of Actavis exchanged hands as compared to its average daily volume of 2,973,900 shares. The stock ranged in a price between $200.12-$205.44 after having opened the day at $203.50 as compared to the previous trading day's close of $197.81. Other companies within the Health Care sector that increased today were: AVANIR Pharmaceuticals ( AVNR), up 45.6%, IsoRay ( ISR), up 29.6%, Adamas Pharmaceuticals ( ADMS), up 15.3% and 22nd Century Group ( XXII), up 14.0%.

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Actavis has a market cap of $34.4 billion and is part of the drugs industry. Shares are up 17.7% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Actavis a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk.

On the negative front, Synthetic Biologics ( SYN), down 30.9%, Auxilium Pharmaceuticals ( AUXL), down 17.7%, Prothena ( PRTA), down 15.8% and Usana Health ( USNA), down 15.7% , were all laggards within the health care sector with GlaxoSmithKline ( GSK) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Submit an article to us!

Markets

DOW 17,974.38 -96.02 -0.53%
S&P 500 2,093.18 -21.31 -1.01%
NASDAQ 4,940.8380 -76.0910 -1.52%

Partners Compare Online Brokers

Top Rated Stocks Top Rated Funds Top Rated ETFs